Previous 10 | Next 10 |
2023-03-16 10:19:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Okyo Pharma (NASDAQ: OKYO ) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of OK-101 . OK-101 is the company’s drug can...
2023-03-16 09:33:00 ET When searching for penny stocks to buy or penny stocks to watch, it’s good to focus on catalysts. Typically valued under $5 per share, these stocks generally attract small and new investors. Even with the glitz and glamour that comes with massive breakouts,...
LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today ann...
2023-03-14 09:54:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Uber (NYSE: UBER ) stock and Lyft (NASDAQ: LYFT ) stock are on the rise Tuesday after a court ruled that the companies’ drivers are contractors . ...
2023-03-14 09:24:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips OKYO Pharma (NASDAQ: OKYO ) stock headed lower on Tuesday after the company revealed details of a stock offering for its American Depositary Shares (ADSs). OKYO Pharma has r...
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUN...
2023-03-13 17:06:25 ET OKYO Pharma ( NASDAQ: OKYO ) on Monday priced the public offering of 3.5 million American Depositary Shares at $1.50 per ADS. The gross proceeds from the offering is expected to be about $5.3 million. The offering is expected to close on March 15, 20...
LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: MarbellaStudio / Shutterstock.com Helbiz (NASDAQ: HLBZ ) stock is on the move Wednesday despite a lack of hard news concerning the electric bike and scooter company. Instead, heavy trading volume is the ma...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Koshiro K / Shutterstock Xpeng (NYSE: XPEV ) stock is worth checking on Wednesday after the EV company released delivery data for February. During February 2023, Xpeng delivered a total of 6,010 Smart EVs...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...